|
|
|
|
|
10.12.25 - 15:24
|
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025.“For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting,” said Dr. Musunuri. “I look forward to sharing more about Ocugen's novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire disease and in turn large patient populations—in both rare and age-related blindness diseases.” Details regarding the fireside chat are as follows:Title: Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal DystrophiesDate: Thursday, December 11, 2025Location: Second Floor Ballroom, Track ...
|
|
|
|
|
19.08.25 - 15:45
|
Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra′s Drug (RTTNews)
|
|
|
PainReform Ltd.'s (PRFX) solar energy business unit, developing next-generation AI-driven solar analytics, DeepSolar, has been accepted into the NVIDIA Connect Program. This gives DeepSolar access to NVIDIA's AI frameworks, development tools, and engineering support to advance DeepSolar Predict, the nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.04.25 - 13:03
|
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors.
“Chip possesses a wealth of experience leading innovative biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. “We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases.”
Mr. Clark has more than three decades of leadership experience in the biopharmaceutical industry. He currently serves as Co-founder and Chief Executive Officer of Vibrant Biomedicines, a venture-backed company developing vaccines that target bacterial pathogens. Before co-founding Vibrant Biomedicines, Mr. Clark served as Chief Executive Officer ...
|
|
|
|
|
|
|
|
|
03.04.25 - 16:33
|
XFRA: 137: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ALDEYRA THERAPEUT.DL-,001 137 US01438T1060
AB/FROM ONWARDS 03.04.2025 16:24 CET...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
